Midpoint MRI as an early predictor of responses to neoadjuvant chemotherapy in patients with breast cancer.

Le résumé fourni par la source

e12615 Background: Breast MRI after completion of neoadjuvant chemotherapy (NAC) has demonstrated high sensitivity and positive predictive value in evaluating response to NAC. It is widely recognized as the most accurate imaging technique for assessing tumor response, outperforming mammography and ultrasound. However, there remains a knowledge gap in its potential as an early predictor of pathological response, when performed at the midpoint of NAC. Here, we investigated the correlation between MRI findings at the midpoint of NAC and subsequent pathological response at definitive surgery. Methods: A retrospective study was performed of patients with breast cancer who received NAC at Mayo Clinic, Florida and had at least 2 breast MRIs, one at midpoint and one either pre- or post-treatment. Patients with prior ipsilateral breast cancer were excluded. Participants were stratified into three molecular subtypes: hormone receptor-positive (HR+), HER2-positive (HER2+), and triple-negative breast cancer (TNBC). All MRIs were re-reviewed by dedicated breast radiologists, with tumor response classified as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) based on RECIST criteria. Pathological outcomes, including pathologic complete response (pCR) and residual cancer burden (RCB), were extracted from pathology reports and confirmed by a single breast pathologist, as indicated. pCR was defined as the absence of residual invasive tumor in both the breast and axillary lymph nodes. Results: A total of 154 patients met inclusion criteria from 2012 to 2022. Similar to previous studies, the positive predictive value for the post-treatment MRI was high at 82.4%, with 14 of 17 patients with imaging complete responses (iCR) achieving pCR. For the midpoint MRI, the positive predictive value for patients with iCR was 100%, with 8 out of 8 patients achieving pCR. Patients with certain subtypes of breast cancer with at least PR in both breast and axillary lymph nodes at midpoint MRI had numerically higher pCR rate, specifically HER2+ (22/37, 59.5%) and TNBC (8/13, 61.5%) but not HR+ tumors (12/45, 26.7%). In contrast, patients with less than PR in either breast or axillary lymph nodes showed numerically lower rate pCR in TNBC (7/18, 38.9%) and HR+ tumors (3/18, 16.7%). However, 15/23 (65.2%) patients with HER2+ tumors achieved pCR despite having less than PR at midpoint MRI. Conclusions: Midpoint breast MRI may serve as an early predictor of pathological response, particularly in patients with iCR. Patients with less than PR, especially those with HR+ and TNBC, have lower chances of achieving pCR. These findings highlight the importance of considering additional therapies for these subgroups of patients to improve the treatment outcomes, as they are less likely to achieve pCR with the current standard neoadjuvant chemotherapy regimen.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.